You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Prospective Evaluation of the Impact of Antiangiogenic Treatment on Cognitive Functions in Metastatic Renal Cancer
|
|---|---|
| Published in |
European Urology Focus , May 2016
|
| DOI | 10.1016/j.euf.2016.04.009 |
| Pubmed ID | |
| Authors |
Florence Joly, Natacha Heutte, Brigitte Duclos, Sabine Noal, Isabelle Léger-Hardy, Sarah Dauchy, Nadine Longato, Laurence Desrues, Nadine Houede, Marie Lange, Emmanuel Sevin, Chantal Rieux, Bénédicte Clarisse, Hélène Castel, Bernard Escudier |
| Abstract |
Little is known about the cognitive effects of antiangiogenic therapies (AATs) in metastatic renal cell carcinoma (mRCC) and their relation with fatigue. To evaluate the impact of AATs on cognition and its connection with fatigue and quality of life (QoL) in patients with mRCC. This prospective study enrolled 75 patients starting AAT as first or second line for mRCC and assessed them at 3 mo (n=58) and 6 mo (n=50). We assessed objective cognitive decline with a neuropsychological battery of tests and cognitive complaint, fatigue, and QoL with validated self-reported questionnaires using the Fisher exact test, Wilcoxon test, and Spearman correlation coefficient. A decline of cognitive functions was observed in 18 patients (31%) including 13 without cognitive impairment at baseline. The score of fatigue was increased in all patients except one. A relationship between cognitive complaints and fatigue was observed (p<0.05) but not with objective cognitive decline. Cognitive complaints and fatigue had a significant impact on most of the domains of QoL (p<0.01). A positive correlation was found between fatigue and inflammatory markers but not with cognition. The main limitation of this study is the absence of a control group. AAT induced cognitive decline in patients with mRCC independently of fatigue. These side effects affecting QoL should be better assessed in clinical trials and taken into account in routine practice. Fatigue is a well-known effect of antiangiogenic therapies (AATs) of cancer. The study performed in patients with treated metastatic renal cancer shows a decline of cognitive functions induced by AATs, such as information-processing speed or working memory, in a third of patients, independently of fatigue. Patients on AATs should be informed of these possible adverse effects. |
X Demographics
The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 40% |
| Italy | 1 | 20% |
| Unknown | 2 | 40% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Science communicators (journalists, bloggers, editors) | 3 | 60% |
| Members of the public | 2 | 40% |
Mendeley readers
The data shown below were compiled from readership statistics for 38 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 38 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 6 | 16% |
| Student > Ph. D. Student | 5 | 13% |
| Other | 3 | 8% |
| Student > Bachelor | 3 | 8% |
| Student > Doctoral Student | 2 | 5% |
| Other | 9 | 24% |
| Unknown | 10 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 9 | 24% |
| Nursing and Health Professions | 5 | 13% |
| Psychology | 5 | 13% |
| Neuroscience | 3 | 8% |
| Agricultural and Biological Sciences | 1 | 3% |
| Other | 4 | 11% |
| Unknown | 11 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 July 2016.
All research outputs
#14,292,663
of 25,394,764 outputs
Outputs from European Urology Focus
#1,049
of 1,440 outputs
Outputs of similar age
#167,127
of 342,411 outputs
Outputs of similar age from European Urology Focus
#29
of 48 outputs
Altmetric has tracked 25,394,764 research outputs across all sources so far. This one is in the 43rd percentile – i.e., 43% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,440 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.8. This one is in the 25th percentile – i.e., 25% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 342,411 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 50% of its contemporaries.
We're also able to compare this research output to 48 others from the same source and published within six weeks on either side of this one. This one is in the 39th percentile – i.e., 39% of its contemporaries scored the same or lower than it.